Please ensure Javascript is enabled for purposes of website accessibility

Why Boston Scientific Corporation Rose 15.7% in April

By Cory Renauer - May 9, 2016 at 12:18PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A stellar earnings report pumped up shares of the cardiac device specialist.

Image source: Boston Scientific.

What: Shares of Boston Scientific Corporation (BSX 1.99%), an interventional medical device specialist, popped 15.5% in April, according to data from S&P Global Market Intelligence. A strong first-quarter earnings and improved outlook provided the boost.

BSX Chart

So what: The company is off to a roaring start this year. Total first-quarter revenue was 13% higher, and when excluding the impact of a recent acquisition, organic revenue grew 8% compared with the same period last year.

Four of the company's seven business segments grew revenue by double digits, leading to a 24% gain in operating profit.

A more optimistic outlook for the rest of the year is what excited the market the most. The company boosted annual revenue growth guidance from between 4% and 7% over 2015 to between 6% and 8%, excluding the recent addition of the male urology portfolio it just bought from Endo International for about $1.6 billion.

Management also expects its adjusted operating margin to widen an extra 0.5% to 24.5%, which sounds awfully good for a company with operations that have ended most of the past 10 years in the red on a GAAP basis.

Now what: Competition in the medical-device business is intense, and size confers an advantage. With about $7.7 billion in trailing-12-month revenue, Boston Scientific isn't a small fry, but compared with a giant like Medtronic, it's struggling just to keep its head above water.

If Abbott can complete its announced acquisition of Boston Scientific's competitor St. Jude Medical, it will have another device juggernaut with more than $25 billion in annual revenue to contend with.  

BSX Revenue (TTM) Chart

Boston Scientific has slowly been returning to top-line growth through acquisition -- which entails a great deal of execution risk. A few wrong moves, and this company could find itself in some trouble.

If you strip away the $12.5 billion in goodwill and other intangible assets from Boston Scientific's balance sheet, its tangible asset value of less than $5.2 billion is a bit less than the $5.4 billion in long-term debt it's carrying. If that doesn't send a chill down your spine, I don't know what will.

If you're committed to holding shares of this device maker, I'd recommend focusing on management's adjusted figures.

BSX Book Value (Annual) Chart

Otherwise, you might notice you're stuck with a growth stock that isn't growing.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Boston Scientific Corporation Stock Quote
Boston Scientific Corporation
BSX
$38.01 (1.99%) $0.74

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.